Phase II Trial of Ofatumumab and Fresh Frozen Plasma in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 29 Oct 2019 Planned End Date changed from 1 Apr 2019 to 1 Mar 2020.
- 29 Oct 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Mar 2020.
- 31 Aug 2018 Biomarkers information updated